EHS 2025 JUNE 4-6 PARIS - FRANCE

Imperial College

London

Incisional Hernia

NHS

Chelsea and Westminster Hospital

Outcomes in Robotic Ventral and Incisional Hernia Repair; the first 50 cases

Zeynah ALHADAD¹, Romilly K Hayward^{1,2}, Jeremy Free¹, Christopher Nicolay², Oliver J Warren^{1,2}

 1 Imperial College London, United Kingdom; 2 Chelsea & Westminster Hospital NHS Fdn Trust

Background	Method
 The proportion of robotic ventral and incisional hernias repairs is increasing. Real-time analyses of patient outcomes provide valuable data regarding feasibility and safety of integrating these techniques in practice. 	 Prospective data capture on patients undergoing ventral or incisional hernia repair during the introduction of robotics into a single-surgeon, high- volume hernia practice. Aim: analysis of perioperative safety profile and efficacy of robotic ventral/incisional hernia repair.
Results	
Jan 2023-Dec 2024: 50 robotic ventral and incisional hemia repairs (figure 1)	 Postoperative Outcomes Complication-free recovery: 90% (n=45) Major complications (CDIII/above): 8% (n=4) Readmission: n=1 (postoperative infection) Return to theatre: n=1 (haematoma evacuation) No mesh explantations. No deaths within 60 days. No early recurrences. Median follow-up: 84 days.
 Figure 1: distribution of surgical techniques used in robotic ventra l'incisional hernia repair Demographics: Male n=22 (44%) Median age 54 (IQR 42–68) 34% ASAI, 44% ASAII, 22% ASA III Perioperative Outcomes Median blood loss: OmL (no transfusions) Conversion to open: 4% (n=2) 	CDII CDIII Complication-free
 Median console time= 48 minutes (IQR 36-72). Median Length of Stay: 1 day (IQR 0-1) 	<i>Figure 2:</i> outcomes following robotic ventral hernia repair CD=Clavien-Dindo Grade

Conclusion

These 50 cases demonstrate the **safe introduction of robotic surgery** into ventral and incisional hernia practice, with **90%** of patients making an entirely **complication freerecovery**, alongside short length of stay, low rates of readmission and return to theatre, and **no** associated mortality or early recurrences.